Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization

Development and validation of an Arabic-language headache questionnaire for population-based surveys

(2017) Naglaa El-Sherbiny et al.   Journal of Pain Research

Impact of depression and anxiety on burden and management of episodic and chronic headaches – a cross-sectional multicentre study in eight Austrian headache centres

(2016) Karin Zebenholzer et al.   JOURNAL OF HEADACHE AND PAIN

Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study

(2016) Giancarlo Comi et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Optimizing therapy early in multiple sclerosis: An evidence-based view

(2015) Tjalf Ziemssen et al.   Multiple Sclerosis and Related Disorders

Postmarketing Safety Profile of Subcutaneous Interferon Beta-1a Given 3 Times Weekly: A Retrospective Administrative Claims Analysis

(2015) Meredith Y. Smith et al.   Journal of Managed Care & Specialty Pharmacy

Patients with chronic headache tend to have more psychological symptoms than those with sporadic episodes of pain

(2014) Maria Aparecida Junqueira Zampieri et al.   ARQUIVOS DE NEURO-PSIQUIATRIA

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

The International Classification of Headache Disorders, 3rd edition (beta version)

(2013)   CEPHALALGIA

Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis

(2013) Anthony T. Reder et al.   Multiple Sclerosis and Related Disorders

Reference programme: Diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd Edition, 2012

(2012) Lars Bendtsen et al.   JOURNAL OF HEADACHE AND PAIN

Frequency and severity of headache is worsened by Interferon-β therapy in patients with multiple sclerosis

(2011) F. Patti et al.   ACTA NEUROLOGICA SCANDINAVICA

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

(2011) Giancarlo Comi et al.   LANCET NEUROLOGY

Tension-type Headache and Migraine in Multiple Sclerosis

(2010) Ilya Kister et al.   Current Pain and Headache Reports

Cross-sectional study assessing long-term safety of interferon- -1b for relapsing-remitting MS

(2010) A. T. Reder et al.   NEUROLOGY

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

(2009) G Giovannoni et al.   Multiple Sclerosis Journal

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY